Wiliam Nicholas Jagoe

Title: Wiliam Nicholas Jagoe: Innovator in Androgen Receptor Research

Introduction

Wiliam Nicholas Jagoe is a notable inventor based in Sandymount, Ireland. He has made significant contributions to the field of androgen receptor research, particularly in developing novel therapeutic strategies for prostate cancer treatment. His work focuses on understanding and modulating the biological effects of androgens, which play a crucial role in various androgen-dependent conditions.

Latest Patents

Wiliam Nicholas Jagoe holds a patent for "Androgen receptor ligands - Non ligand binding pocket antagonists for the human androgen receptor." This patent addresses the need for alternative therapies in prostate cancer treatment, particularly in light of the challenges posed by prolonged ligand binding pocket-targeting therapies. The disclosed class of non-steroidal, small molecule AR antagonists demonstrates full antagonism in androgen receptors with low micromolar potency and high selectivity over estrogen and glucocorticoid receptors.

Career Highlights

Jagoe is affiliated with the College of the Holy and Undivided Trinity of Queen Elizabeth, near Dublin. His research has contributed to the understanding of androgen receptor modulation and its implications for therapeutic interventions in prostate cancer. His innovative approach offers promising alternatives to classical therapies, which often lead to androgen resistance.

Collaborations

Wiliam Nicholas Jagoe has collaborated with notable colleagues, including David George Lloyd and Darren Fayne. These collaborations have further enriched his research and contributed to advancements in the field of androgen receptor antagonism.

Conclusion

Wiliam Nicholas Jagoe's work in androgen receptor research exemplifies the importance of innovation in developing effective treatments for prostate cancer. His contributions pave the way for new therapeutic strategies that may improve patient outcomes in androgen-dependent conditions.